Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory properties

Journal of Vascular Surgery

Volumn 43, Issue 4, 2006, Pages 816-823

  Haller, Carolyn A ^a   Cui, Wanxing ^a   Wen, Jing ^a   Robson, Simon C ^b   Chaikof, Elliot L ^a,c  

^a EMORY UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Georgia Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; LIPOSOME; NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE; PHOSPHATASE; PROTEIN CD39; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PURIFICATION; ENZYME RECONSTITUTION; HYDROLYSIS; IN VITRO STUDY; LIPID BILAYER; LIPID MEMBRANE; LIPID VESICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ANIMALS; ANTIGENS, CD; APYRASE; BIOPSY, NEEDLE; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; LIPOSOMES; MICE; MICE, INBRED STRAINS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PULMONARY EMBOLISM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THROMBOPLASTIN; TIME FACTORS;

EID: 33645738564     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2005.11.057     Document Type: Article

References (52)

1. Kaczmarek E., Koziak K., Sevigny J., Siegel J.B., Anrather J., Beaudoin A.R., et al. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 271 (1996) 33116-33122
2. Koziak K., Kaczmarek E., Kittel A., Sevigny J., Blusztajn J.K., Schulte Am Esch II J., et al. Palmitoylation targets CD39/endothelial ATP diphosphohydrolase to caveolae. J Biol Chem 275 (2000) 2057-2062
3. Marcus A.J., Broekman M.J., Drosopoulos J.H., Pinsky D.J., Islam N., and Maliszewsk C.R. Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases. Ital Heart J 2 (2001) 824-830
4. Marcus A.J., Safier L.B., Hajjar K.A., Ullman H.L., Islam N., Broekman M.J., et al. Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells. J Clin Invest 88 (1991) 1690-1696
5. Sevigny J., Sundberg C., Braun N., Guckelberger O., Csizmadia E., Qawi I., et al. Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation. Blood 99 (2002) 2801-2809
6. Vischer U.M., and Wollheim C.B. Purine nucleotides induce regulated secretion of von Willebrand factor: involvement of cytosolic Ca2+ and cyclic adenosine monophosphate-dependent signaling in endothelial exocytosis. Blood 91 (1998) 118-127
7. Pinsky D.J., Broekman M.J., Peschon J.J., Stocking K.L., Fujita T., Ramasamy R., et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 109 (2002) 1031-1040
8. Enjyoji K., Sevigny J., Lin Y., Frenette P.S., Christie P.D., Esch II J.S., et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 5 (1999) 1010-1017
9. Robson S.C., Kaczmarek E., Siegel J.B., Candinas D., Koziak K., Millan M., et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 185 (1997) 153-163
10. Imai M., Kaczmarek E., Koziak K., Sevigny J., Goepfert C., Guckelberger O., et al. Suppression of ATP diphosphohydrolase/CD39 in human vascular endothelial cells. Biochemistry 38 (1999) 13473-13479
11. Gangadharan S.P., Imai M., Rhynhart K.K., Sevigny J., Robson S.C., and Conte M.S. Targeting platelet aggregation: CD39 gene transfer augments nucleoside triphosphate diphosphohydrolase activity in injured rabbit arteries. Surgery 130 (2001) 296-303
12. Dwyer K.M., Robson S.C., Nandurkar H.H., Campbell D.J., Gock H., Murray-Segal L.J., et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 113 (2004) 1440-1446
13. Kaneider N.C., Egger P., Dunzendorfer S., Noris P., Balduini C.L., Gritti D., et al. Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: Effects on Rho-GTPase and adenosine nucleotide metabolism. Arterioscler Thromb Vasc Biol 22 (2002) 894-900
14. Koyamada N., Miyatake T., Candinas D., Hechenleitner P., Siegel J., Hancock W.W., et al. Apyrase administration prolongs discordant xenograft survival. Transplantation 62 (1996) 1739-1743
15. Gayle III R.B., Maliszewski C.R., Gimpel S.D., Schoenborn M.A., Caspary R.G., Richards C., et al. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39. J Clin Invest 101 (1998) 1851-1859
16. Belayev L., Khoutorova L., Deisher T.A., Belayev A., Busto R., Zhang Y., et al. Neuroprotective effect of SolCD39, a novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats. Stroke 34 (2003) 758-763
17. Dai J., Liu J., Deng Y., Smith T.M., and Lu M. Structure and protein design of a human platelet function inhibitor. Cell 116 (2004) 649-659
18. Maliszewski C.R., Delespesse G.J., Schoenborn M.A., Armitage R.J., Fanslow W.C., Nakajima T., et al. The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization. J Immunol 153 (1994) 3574-3583
19. Handa M., and Guidotti G. Purification and cloning of a soluble ATP-diphosphohydrolase (apyrase) from potato tubers (Solanum tuberosum). Biochem Biophys Res Commun 218 (1996) 916-923
20. Schulte am Esch J., Sevigny J., Kaczmarek E., Siegel J.B., Imai M., Koziak E., et al. Structural elements and limited proteolysis of CD39 influence ATP diphosphohydrolase activity. Biochemistry 38 (1999) 2248-2258
21. Yang F., Hicks-Berger C.A., Smith T.M., and Kirley T.L. Site-directed mutagenesis of human nucleoside triphosphate diphosphohydrolase 3: the importance of residues in the apyrase conserved regions. Biochemistry 40 (2001) 3943-3950
22. Grinthal A., and Guidotti G. Substitution of His59 converts CD39 apyrase into an ADPase in a quaternary structure dependent manner. Biochemistry 39 (2000) 9-16
23. Drosopoulos J.H., Broekman M.J., Islam N., Maliszewski C.R., Gayle R.B., and Marcus A.J. Site-directed mutagenesis of human endothelial cell ecto-ADPase/soluble CD39: requirement of glutamate 174 and serine 218 for enzyme activity and inhibition of platelet recruitment. Biochemistry 39 (2000) 6936-6943
24. Plesner L. Ecto-ATPases: identities and functions. Int Rev Cytol 158 (1995) 141-214
25. Wang T.F., Ou Y., and Guidotti G. The transmembrane domains of ectoapyrase (CD39) affect its enzymatic activity and quaternary structure. J Biol Chem 273 (1998) 24814-24821
26. Grinthal A., and Guidotti G. Dynamic motions of CD39 transmembrane domains regulate and are regulated by the enzymatic active site. Biochemistry 43 (2004) 13849-13858
27. Papanikolaou A., Papafotika A., Murphy C., Papamarcaki T., Tsolas O., Drab M., et al. Cholesterol-dependent lipid assemblies regulate the activity of the ecto-nucleotidase CD39. J Biol Chem 280 (2005) 26406-26414
28. Kozak M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 15 (1987) 8125-8148
29. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
30. Ames B.N. Assay of inorganic phosphate, total phosphate and phosphatases. Methods Enzymol 8 (1966) 115-117
31. Leon C., Freund M., Ravanat C., Baurand A., Cazenave J.P., and Gachet C. Key role of the P2Y receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y-knockout mice and mice treated with a P2Y antagonist. Circulation 103 (2001) 718-723
32. The EPISTENT Investigators. Randomised placebo-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 352 (1998) 87-92
33. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 349 (1997) 1429-1435
34. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330 (1994) 956-961
35. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 (1997) 1689-1696
36. Topol E.J., Lincoff A.M., Kereiakes D.J., Kleiman N.S., Cohen E.A., Ferguson J.J., et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 113 (2002) 1-6
37. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., et al. CD40 ligand on activated platelet triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
38. Heeschen C., Dimmeler S., Hamm C.W., van den Brand M.J., Boersma E., Zeiher A.M., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
39. Jarvis B., and Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 60 (2000) 347-377
40. Kroll M.H., and Schafer A.I. Biochemical mechanisms of platelet activation. Blood 74 (1989) 1181-1195
41. Cattaneo M., Canciani M.T., Lecchi A., Kinlough-Rathbone R.L., Packham M.A., Mannucci P.M., et al. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood 75 (1990) 1081-1086
42. Gachet C., Hechler B., Leon C., Vial C., Leray C., Ohlmann P., et al. Activation of ADP receptors and platelet function. Thrombosis Haemostasis 78 (1997) 271-275
43. Bertrand M.E., Rupprecht H.J., Urban P., Gershlick A.H., and CLASSIC Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102 (2000) 624-629
44. Cannon C.P., and CAPRIE Investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 90 (2002) 760-762
45. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
46. Leon M.B., Baim D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339 (1998) 1665-1671
47. Urban P., Macaya C., Rupprecht H.J., Kiemeneij F., Emanuelsson H., Fontanelli A., et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98 (1998) 2126-2132
48. Schomig A., Neumann F.J., Walter H., Schuhlen H., Hadamitzky M., Zitzmann-Roth E.M., et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 29 (1997) 28-34
49. Gurbel P.A., Malinin A.I., Callahan K.P., Serebruany V.L., and O'Connor C.M. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. Am J Cardiol 90 (2002) 312-315
50. Marcus A.J., Broekman M.J., Drosopoulos J.H., Islam N., Pinsky D.J., Sesti C., et al. Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1). J Thromb Haemost 1 (2003) 2497-2509
51. Sampram E.S., and Ouriel K. In vitro verification of antithrombotic effect of recombinant soluble nucleotide triphosphate diphosphohydrolase 1. J Vasc Interven Rad 15 (2004) 379-384
52. Galvin J.B., Kurosawa S., Moore K., Esmon C.T., and Esmon N.L. Reconstitution of rabbit thrombomodulin into phospholipid vesicles. J Biol Chem 262 (1987) 2199-2205